C4 Therapeutics Q3 2026 net loss narrows 32% year over year to $21.84 million

Bitget2026/11/05 12:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

C4 Therapeutics’ third-quarter 2026 net loss narrowed 32% year over year to $21.84 million.
Revenue fell 25% year over year to $8.47 million.
Cash, cash equivalents and marketable securities totaled $274.69 million at September 30, 2026, with funding expected through the end of 2028.
The Phase 2 MOMENTUM trial remains on track to complete enrollment in first-quarter 2027, with initial response data expected in second-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870816) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

C4 Therapeutics Q3 2026 net loss narrows 32% year over year to $21.84 million

You may also like

Crypto prices